Bohacek, R. S., McMartin, C. & Guida, W. C. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16, 3–50 (1996).
Ertl, P. Cheminformatics analysis of organic substituents: identification of the most common substituents, calculation of substituent properties, and automatic identification of drug-like bioisosteric groups. J. Chem. Inf. Comput. Sci. 43, 374–380 (2003).
Fink, T., Bruggesser, H. & Reymond, J. L. Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew. Chem. Int. Ed. 44, 1504–1508 (2005).
Chevillard, F. & Kolb, P. SCUBIDOO: a large yet screenable and easily searchable database of computationally created chemical compounds optimized toward high likelihood of synthetic tractability. J. Chem. Inf. Model. 55, 1824–1835 (2015).
Keserü, G. M. & Makara, G. M. The influence of lead discovery strategies on the properties of drug candidates. Nat. Rev. Drug Discov. 8, 203–212 (2009).
McGovern, S. L., Caselli, E., Grigorieff, N. & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712–1722 (2002).
Brenner, S. & Lerner, R. A. Encoded combinatorial chemistry. Proc. Natl Acad. Sci. USA 89, 5381–5383 (1992).
Ahn, S. et al. Allosteric “beta-blocker” isolated from a DNA-encoded small molecule library. Proc. Natl Acad. Sci. USA 114, 1708–1713 (2017).
Goodnow, R. A. Jr, Dumelin, C. E. & Keefe, A. D. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat. Rev. Drug Discov. 16, 131–147 (2017).
Jorgensen, W. L. The many roles of computation in drug discovery. Science 303, 1813–1818 (2004).
de Graaf, C. et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H1 receptor. J. Med. Chem. 54, 8195–8206 (2011).
Katritch, V. et al. Structure-based discovery of novel chemotypes for adenosine A2A receptor antagonists. J. Med. Chem. 53, 1799–1809 (2010).
Manglik, A. et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537, 185–190 (2016).
Wang, S. et al. D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. Science 358, 381–386 (2017).
Negri, A. et al. Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening. J. Chem. Inf. Model. 53, 521–526 (2013).
Jazayeri, A., Andrews, S. P. & Marshall, F. H. Structurally enabled discovery of adenosine A2A receptor antagonists. Chem. Rev. 117, 21–37 (2017).
Lane, J. R. et al. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Mol. Pharmacol. 84, 794–807 (2013).
Langmead, C. J. et al. Identification of novel adenosine A2A receptor antagonists by virtual screening. J. Med. Chem. 55, 1904–1909 (2012).
Becker, O. M. et al. G protein-coupled receptors: in silico drug discovery in 3D. Proc. Natl Acad. Sci. USA 101, 11304–11309 (2004).
Kooistra, A. J. et al. Function-specific virtual screening for GPCR ligands using a combined scoring method. Sci. Rep. 6, 28288 (2016).
Congreve, M. et al. Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design. J. Med. Chem. 55, 1898–1903 (2012).
Kiss, R. et al. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J. Med. Chem. 51, 3145–3153 (2008).
Oprea, T. I. & Gottfries, J. Chemography: the art of navigating in chemical space. J. Comb. Chem. 3, 157–166 (2001).
Mysinger, M. M., Carchia, M., Irwin, J. J. & Shoichet, B. K. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J. Med. Chem. 55, 6582–6594 (2012).
Bemis, G. W. & Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 39, 2887–2893 (1996).
Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45, D945–D954 (2017).
Katz, B. A. et al. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site. J. Mol. Biol. 307, 1451–1486 (2001).
Congreve, M., Langmead, C. J., Mason, J. S. & Marshall, F. H. Progress in structure based drug design for G protein-coupled receptors. J. Med. Chem. 54, 4283–4311 (2011).
Vaidehi, N. Dynamics and flexibility of G-protein-coupled receptor conformations and their relevance to drug design. Drug Discov. Today 15, 951–957 (2010).
Irwin, J. J. & Shoichet, B. K. Docking screens for novel ligands conferring new biology. J. Med. Chem. 59, 4103–4120 (2016).
Vass, M. et al. in Computational Methods for GPCR Drug Discovery (Heifetz, A.) Ch. 4, 73–113 (Humana, Springer, New Jersey, 2018).
Isberg, V. et al. Generic GPCR residue numbers – aligning topology maps while minding the gaps. Trends Pharmacol. Sci. 36, 22–31 (2015).
McCorvy, J. D. et al. Structural determinants of 5-HT2B receptor activation and biased agonism. Nat. Struct. Mol. Biol. 25, 787–796 (2018).
Powers, R. A., Morandi, F. & Shoichet, B. K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC β-lactamase. Structure 10, 1013–1023 (2002).
Feng, B. Y. et al. A high-throughput screen for aggregation-based inhibition in a large compound library. J. Med. Chem. 50, 2385–2390 (2007).
Babaoglu, K. et al. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against β-lactamase. J. Med. Chem. 51, 2502–2511 (2008).
Rowley, M. et al. 5-(4-chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J. Med. Chem. 39, 1943–1945 (1996).
Enguehard-Gueiffier, C. et al. 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J. Med. Chem. 49, 3938–3947 (2006).
Löber, S., Hübner, H. & Gmeiner, P. Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg. Med. Chem. Lett. 16, 2955–2959 (2006).
Lindsley, C. W. & Hopkins, C. R. Return of D4 dopamine receptor antagonists in drug discovery. J. Med. Chem. 60, 7233–7243 (2017).
Tirado-Rives, J. & Jorgensen, W. L. Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. J. Med. Chem. 49, 5880–5884 (2006).
Abagyan, R., Totrov, M. & Kuznetsov, D. ICM—a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation. J. Comput. Chem. 15, 488–506 (1994).
Halgren, T. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 47, 1750–1759 (2004).
Goodsell, D. S. & Olson, A. J. Automated docking of substrates to proteins by simulated annealing. Proteins 8, 195–202 (1990).
Kufareva, I., Katritch, V., Stevens, R. C. & Abagyan, R. Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: meeting new challenges. Structure 22, 1120–1139 (2014).
Kramer, B., Rarey, M. & Lengauer, T. Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37, 228–241 (1999).
McGann, M. FRED pose prediction and virtual screening accuracy. J. Chem. Inf. Model. 51, 578–596 (2011).
Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267, 727–748 (1997).
Corbeil, C. R., Williams, C. I. & Labute, P. Variability in docking success rates due to dataset preparation. J. Comput. Aided Mol. Des. 26, 775–786 (2012).
Hawkins, P. C., Skillman, A. G., Warren, G. L., Ellingson, B. A. & Stahl, M. T. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J. Chem. Inf. Model. 50, 572–584 (2010).
Hawkins, G. D. et al. AMSOL version 7.1 https://comp.chem.umn.edu/amsol/ (2004).
Wei, B. Q., Baase, W. A., Weaver, L. H., Matthews, B. W. & Shoichet, B. K. A model binding site for testing scoring functions in molecular docking. J. Mol. Biol. 322, 339–355 (2002).
Mysinger, M. M. & Shoichet, B. K. Rapid context-dependent ligand desolvation in molecular docking. J. Chem. Inf. Model. 50, 1561–1573 (2010).
Sterling, T. & Irwin, J. J. ZINC 15—ligand discovery for everyone. J. Chem. Inf. Model. 55, 2324–2337 (2015).
Barelier, S. et al. Increasing chemical space coverage by combining empirical and computational fragment screens. ACS Chem. Biol. 9, 1528–1535 (2014).
Gray, D. L. et al. Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. Nat. Commun. 9, 674 (2018).
Carlsson, J. et al. Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat. Chem. Biol. 7, 769–778 (2011).
Meng, E. C., Shoichet, B. K. & Kuntz, I. D. Automated docking with gridb-based energy evaluation. J. Comput. Chem. 13, 505–524 (1992).
Sharp, K. A., Friedman, R. A., Misra, V., Hecht, J. & Honig, B. Salt effects on polyelectrolyte-ligand binding: comparison of Poisson–Boltzmann, and limiting law/counterion binding models. Biopolymers 36, 245–262 (1995).
Gallagher, K. & Sharp, K. Electrostatic contributions to heat capacity changes of DNA-ligand binding. Biophys. J. 75, 769–776 (1998).
Coleman, R. G., Carchia, M., Sterling, T., Irwin, J. J. & Shoichet, B. K. Ligand pose and orientational sampling in molecular docking. PLoS ONE 8, e75992 (2013).
Tolmachev, A. et al. Expanding synthesizable space of disubstituted 1,2,4-oxadiazoles. ACS Comb. Sci. 18, 616–624 (2016).
Eidam, O. et al. Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J. Med. Chem. 53, 7852–7863 (2010).
Kabsch, W. XDS. Acta Crystallogr. D 66, 125–132 (2010).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240–255 (1997).
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213–221 (2010).
Eidam, O. et al. Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo. Proc. Natl Acad. Sci. USA 109, 17448–17453 (2012).
Feng, B. Y. & Shoichet, B. K. A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550–553 (2006).
Allen, J. A. et al. Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl Acad. Sci. USA 108, 18488–18493 (2011).
Carpenter, B. et al. Stan: a probabilistic programming language. J. Stat. Softw. 1, 1–32 (2017).
Ryan, E. G., Drovandi, C. C., McGree, J. M. & Pettitt, A. N. A review of modern computational algorithms for Bayesian optimal design. Int. Stat. Rev. 84, 128–154 (2016).
Rainforth, T., Cornish, R., Yang, H., Warrington, A. & Wood, F. On Nesting Monte Carlo Estimators. In Proc. 35th International Conference on Machine Learning PMLR 80 (eds Dy, J. & Krause, A.) 4267–4276 (2018).